{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:04:38Z","timestamp":1793250278047,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["BFU2010-19300"],"award-info":[{"award-number":["BFU2010-19300"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2022-1381850B-I00"],"award-info":[{"award-number":["PID2022-1381850B-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FPU20\/03954"],"award-info":[{"award-number":["FPU20\/03954"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FPU20\/03957"],"award-info":[{"award-number":["FPU20\/03957"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01301"],"award-info":[{"award-number":["PI20\/01301"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00652"],"award-info":[{"award-number":["PI23\/00652"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES18"],"award-info":[{"award-number":["INVES18"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PEMP-0036-2020"],"award-info":[{"award-number":["PEMP-0036-2020"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["BIO-0139"],"award-info":[{"award-number":["BIO-0139"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012514","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n","doi-asserted-by":"publisher","award":["Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n"],"award-info":[{"award-number":["Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n"]}],"id":[{"id":"10.13039\/501100012514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-024-05515-6","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T02:28:47Z","timestamp":1735266527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The splicing machinery is dysregulated and represents a therapeutic vulnerability in breast cancer"],"prefix":"10.1007","volume":"82","author":[{"given":"Natalia","family":"Herm\u00e1n-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel E.","family":"G-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Jim\u00e9nez-Vacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Yubero-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"L\u00f3pez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Romero-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Raya-Povedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"\u00c1lvarez-Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justo P.","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal M.","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-2179","authenticated-orcid":false,"given":"Manuel D.","family":"Gahete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"issue":"3","key":"5515_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"5515_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cac2.12207","volume":"41","author":"S Lei","year":"2021","unstructured":"Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K et al (2021) Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun 41(11):1183\u20131194","journal-title":"Cancer Commun"},{"key":"5515_CR3","doi-asserted-by":"crossref","unstructured":"Harbeck N, Gnant M (2017) Breast cancer. Vol. 389, the Lancet. Lancet Publishing Group, pp 1134\u20131150","DOI":"10.1016\/S0140-6736(16)31891-8"},{"key":"5515_CR4","doi-asserted-by":"crossref","unstructured":"Yersal O, Barutca S (2014) Biological subtypes of breast cancer: prognostic and therapeutic implications. World Journal of Clinical Oncology, vol 5. Baishideng Publishing Group Co., Limited, pp 412\u2013424","DOI":"10.5306\/wjco.v5.i3.412"},{"key":"5515_CR5","doi-asserted-by":"crossref","unstructured":"Waks AG, Winer EP (2019) 321, JAMA - journal of the American Medical Association. Breast Cancer Treatment: a review. American Medical Association, pp 288\u2013300","DOI":"10.1001\/jama.2018.19323"},{"key":"5515_CR6","doi-asserted-by":"crossref","unstructured":"Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F (2015) Management of locally advanced breast cancer-perspectives and future directions. Nature Reviews Clinical Oncology, vol 12. Nature Publishing Group, pp 147\u2013162","DOI":"10.1038\/nrclinonc.2015.13"},{"key":"5515_CR7","doi-asserted-by":"crossref","unstructured":"Derakhshan F, Reis-Filho JS (2021) Pathogenesis of Triple-negative breast Cancer. Vol. 17, Annual Review of Pathology: mechanisms of Disease. Annual Reviews Inc., pp 181\u2013204","DOI":"10.1146\/annurev-pathol-042420-093238"},{"key":"5515_CR8","doi-asserted-by":"crossref","unstructured":"Asleh K, Riaz N, Nielsen TO (2022) Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. Journal of Experimental and Clinical Cancer Research, vol 41. BioMed Central Ltd","DOI":"10.1186\/s13046-022-02476-1"},{"key":"5515_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2009.12.002","volume":"36","author":"A Bosch","year":"2010","unstructured":"Bosch A, Eroles P, Zaragoza R, Vi\u00f1a JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206\u2013215","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"5515_CR10","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.ccell.2021.11.001","volume":"39","author":"SB Koh","year":"2021","unstructured":"Koh SB, Ellisen LW (2021) Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer. Cancer Cell 39(12):1562\u20131564","journal-title":"Cancer Cell"},{"key":"5515_CR11","doi-asserted-by":"crossref","unstructured":"Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. JNCCN Journal of the National Comprehensive Cancer Network, vol 18. Harborside, pp 479\u2013489","DOI":"10.6004\/jnccn.2020.7554"},{"key":"5515_CR12","doi-asserted-by":"crossref","unstructured":"Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R (2018) Breast cancer genomics and immuno-oncological markers to guide immune therapies. Seminars in Cancer Biology, vol 52. Academic, pp 178\u2013188","DOI":"10.1016\/j.semcancer.2017.11.003"},{"key":"5515_CR13","doi-asserted-by":"crossref","unstructured":"Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A et al (2021) Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. NPJ Breast Cancer.;7(1)","DOI":"10.1038\/s41523-021-00312-x"},{"key":"5515_CR14","doi-asserted-by":"crossref","unstructured":"Ragupathi A, Singh M, Perez AM, Zhang D (2023) Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: clinical outcomes and mechanistic insights. Frontiers in Cell and Developmental Biology, vol 11. Frontiers Media S.A.","DOI":"10.3389\/fcell.2023.1133472"},{"key":"5515_CR15","doi-asserted-by":"crossref","unstructured":"Frankiw L, Baltimore D, Li G (2019) Alternative mRNA splicing in cancer immunotherapy. Nature Reviews Immunology, vol 19. Nature Publishing Group, pp 675\u2013687","DOI":"10.1038\/s41577-019-0195-7"},{"key":"5515_CR16","doi-asserted-by":"crossref","unstructured":"Stanley RF, Abdel-Wahab O (2022) Dysregulation and therapeutic targeting of RNA splicing in cancer. Vol. 3, Nature Cancer. Nature Research, pp 536\u2013546","DOI":"10.1038\/s43018-022-00384-z"},{"key":"5515_CR17","doi-asserted-by":"crossref","unstructured":"Lee SCW, Abdel-Wahab O (2016) Therapeutic targeting of splicing in cancer, vol 22. Nature Medicine. Nature Publishing Group, pp 976\u2013986","DOI":"10.1038\/nm.4165"},{"key":"5515_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczuk\u00f3w O (2023) RNA splicing dysregulation and the hallmarks of cancer. Nat Reviews Cancer Nat Res 23:135\u2013155","journal-title":"Nat Reviews Cancer Nat Res"},{"key":"5515_CR19","doi-asserted-by":"crossref","unstructured":"Gahete MD, Herman-Sanchez N, Fuentes-Fayos AC, Lopez-Canovas JL, Luque RM, Gahete MD (2022) Dysregulation of splicing variants and spliceosome components in breast cancer. Endocrine-Related Cancer, vol 29. BioScientifica Ltd. p. R123-R142N","DOI":"10.1530\/ERC-22-0019"},{"key":"5515_CR20","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, G\u00f3mez-G\u00f3mez E, Fuentes-Fayos AC, Le\u00f3n-Gonz\u00e1lez AJ et al (2020) Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer: SNRNP200, SRSF3 and SRRM1 as novel therapeutic targets for prostate cancer. EBioMedicine.;51","DOI":"10.1016\/j.ebiom.2019.11.008"},{"key":"5515_CR21","doi-asserted-by":"crossref","unstructured":"Fuentes-Fayos AC, P\u00e9rez-G\u00f3mez JM, G-Garc\u00eda E, Jim\u00e9nez-Vacas M, Blanco-Acevedo JM, S\u00e1nchez-S\u00e1nchez C (2022) R, SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR\/\u00df-catenin pathways imbalances. J Experimental Clin Cancer Res.;41(1)","DOI":"10.1186\/s13046-022-02241-4"},{"issue":"11","key":"5515_CR22","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1093\/brain\/awaa273","volume":"143","author":"AC Fuentes-Fayos","year":"2021","unstructured":"Fuentes-Fayos AC, Vazquez-Borrego MC, Jimenez-Vacas JM, Bejarano L, Pedraza-Arevalo S, Lopez FL et al (2021) Splicing machinery dysregulation drives glioblastoma development\/aggressiveness: oncogenic role of SRSF3. Brain 143(11):3273\u20133293","journal-title":"Brain"},{"key":"5515_CR23","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-C\u00e1novas JL, Herm\u00e1n\u2010S\u00e1nchez N, Moreno\u2010Montilla MT, del Rio\u2010Moreno M, Alors\u2010Perez E, S\u00e1nchez\u2010Frias ME et al (2022) Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing. Clin Transl Med.;12(11)","DOI":"10.1002\/ctm2.1102"},{"key":"5515_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2020.10.010","volume":"496","author":"JL L\u00f3pez-C\u00e1novas","year":"2021","unstructured":"L\u00f3pez-C\u00e1novas JL, del Rio-Moreno M, Garc\u00eda-Fernandez H, Jim\u00e9nez-Vacas JM, Moreno-Montilla MT, S\u00e1nchez-Frias ME et al (2021) Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. Cancer Lett 496:72\u201383","journal-title":"Cancer Lett"},{"key":"5515_CR25","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cort\u00e9s E, Dios E, Moreno-Moreno P et al (2019) Splicing machinery is dysregulated in pituitary neuroendocrine tumors and is associated with aggressiveness features. Cancers (Basel).;11(10)","DOI":"10.3390\/cancers11101439"},{"key":"5515_CR26","doi-asserted-by":"crossref","unstructured":"Alors-Perez E, Bl\u00e1zquez-Encinas R, Alcal\u00e1 S, Viyuela-Garc\u00eda C, Pedraza-Arevalo S, Herrero-Aguayo V et al (2021) Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J Experimental Clin Cancer Res.;40(1)","DOI":"10.1186\/s13046-021-02153-9"},{"key":"5515_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.trsl.2022.07.005","volume":"251","author":"S Pedraza-Arevalo","year":"2023","unstructured":"Pedraza-Arevalo S, Alors-P\u00e9rez E, Bl\u00e1zquez-Encinas R, Herrera-Mart\u00ednez AD, Jim\u00e9nez-Vacas JM, Fuentes-Fayos AC et al (2023) Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors. Translational Res 251:63\u201373","journal-title":"Translational Res"},{"key":"5515_CR28","doi-asserted-by":"crossref","unstructured":"Luque RM, L\u00f3pez-S\u00e1nchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL, Yubero-Serrano EM et al (2017) Breast cancer is associated to impaired glucose\/insulin homeostasis in premenopausal obese\/overweight patients [Internet]. Vol. 8, Oncotarget. www.impactjournals.com\/oncotarget\/","DOI":"10.18632\/oncotarget.20399"},{"key":"5515_CR29","doi-asserted-by":"crossref","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A et al (2020) Visualizing and interpreting cancer genomics data via the Xena platform, vol 38. Nature Biotechnology. Nature Research, pp 675\u2013678","DOI":"10.1038\/s41587-020-0546-8"},{"issue":"7403","key":"5515_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346\u2013352","journal-title":"Nature"},{"key":"5515_CR31","doi-asserted-by":"crossref","unstructured":"Vandesompele J, De Preter K, Pattyn ilip, Poppe B, Van Roy N, De Paepe A et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes [Internet]. http:\/\/genomebiology.com\/2002\/3\/7\/research\/0034.1Correspondence:.rankSpeleman","DOI":"10.1186\/gb-2002-3-7-research0034"},{"issue":"3","key":"5515_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/carcin\/bgx146","volume":"39","author":"D Rinc\u00f3n-Fern\u00e1ndez","year":"2018","unstructured":"Rinc\u00f3n-Fern\u00e1ndez D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD et al (2018) In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. Carcinogenesis 39(3):447\u2013457","journal-title":"Carcinogenesis"},{"issue":"W1","key":"5515_CR33","doi-asserted-by":"publisher","first-page":"W388","DOI":"10.1093\/nar\/gkab382","volume":"49","author":"Z Pang","year":"2021","unstructured":"Pang Z, Chong J, Zhou G, De Lima Morais DA, Chang L, Barrette M et al (2021) MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res 49(W1):W388\u2013W396","journal-title":"Nucleic Acids Res"},{"issue":"7391","key":"5515_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603\u2013607","journal-title":"Nature"},{"key":"5515_CR35","doi-asserted-by":"crossref","unstructured":"Elhasnaoui J, Ferrero G, Miano V, Franchitti L, Tarulli I, Coscujuela Tarrero L et al (2022) A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen receptor \u03b1 modulates the alternative transcriptome of luminal breast Cancer. Int J Mol Sci.;23(14)","DOI":"10.3390\/ijms23147835"},{"key":"5515_CR36","doi-asserted-by":"crossref","unstructured":"Liu X, Wang Q, Song S, Feng M, Wang X, Li L et al (2020) Epithelial splicing regulatory protein 1 is overexpressed in breast cancer and predicts poor prognosis for breast cancer patients. Med Sci Monit.;27","DOI":"10.12659\/MSM.931102"},{"key":"5515_CR37","doi-asserted-by":"crossref","unstructured":"Ahuja N, Ashok C, Natua S, Pant D, Cherian A, Pandkar MR et al (2020) Hypoxia-induced TGF-\u03b2\u2013RBFOX2\u2013ESRP1 axis regulates human MENA alternative splicing and promotes EMT in breast cancer. NAR Cancer.;2(3)","DOI":"10.1093\/narcan\/zcaa021"},{"key":"5515_CR38","doi-asserted-by":"crossref","unstructured":"G\u00f6kmen-Polar Y, Neelamraju Y, Goswami CP, Gu Y, Gu X, Nallamothu G et al (2019) Splicing factor ESRP 1 controls ER \u2010positive breast cancer by altering metabolic pathways. EMBO Rep.;20(2)","DOI":"10.15252\/embr.201846078"},{"key":"5515_CR39","doi-asserted-by":"crossref","unstructured":"Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E et al (2017) Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer [Internet]. Vol. 8. www.impactjournals.com\/oncotarget","DOI":"10.18632\/oncotarget.13682"},{"key":"5515_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.trsl.2019.07.001","volume":"212","author":"JM Jim\u00e9nez-Vacas","year":"2019","unstructured":"Jim\u00e9nez-Vacas JM, Herrero-Aguayo V, G\u00f3mez-G\u00f3mez E, Le\u00f3n-Gonz\u00e1lez AJ, S\u00e1ez-Mart\u00ednez P, Alors-P\u00e9rez E et al (2019) Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Translational Res 212:89\u2013103","journal-title":"Translational Res"},{"key":"5515_CR41","volume-title":"Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics","author":"LM Urbanski","year":"2018","unstructured":"Urbanski LM, Leclair N, Anczuk\u00f3w O (2018) Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics, vol 9. RNA. Blackwell Publishing Ltd, Wiley Interdisciplinary Reviews"},{"issue":"10","key":"5515_CR42","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/jmcb\/mjz033","volume":"11","author":"Q Yang","year":"2019","unstructured":"Yang Q, Zhao J, Zhang W, Chen D, Wang Y (2019) Aberrant alternative splicing in breast cancer. J Mol Cell Biol 11(10):920\u2013929","journal-title":"J Mol Cell Biol"},{"key":"5515_CR43","doi-asserted-by":"crossref","unstructured":"Aversa R, Sorrentino A, Esposito R, Ambrosio MR, Amato A, Zambelli A et al (2016) Alternative splicing in adhesion- and motility-related genes in breast cancer. Int J Mol Sci;17(1)","DOI":"10.3390\/ijms17010121"},{"issue":"2","key":"5515_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles A, Lehmann K, Van, Toussaint NC, H\u00fcser M, Stark SG, Sachsenberg T et al (2018) Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 patients. Cancer Cell 34(2):211\u2013224e6","journal-title":"Cancer Cell"},{"issue":"9","key":"5515_CR45","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1016\/j.celrep.2019.10.110","volume":"29","author":"SH Park","year":"2019","unstructured":"Park SH, Brugiolo M, Akerman M, Das S, Urbanski L, Geier A et al (2019) Differential functions of splicing factors in Mammary Transformation and breast Cancer metastasis. Cell Rep 29(9):2672\u20132688e7","journal-title":"Cell Rep"},{"issue":"12","key":"5515_CR46","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1158\/1535-7163.MCT-17-0461","volume":"16","author":"S Chan","year":"2017","unstructured":"Chan S, Sridhar P, Kirchner R, Lock YJ, Herbert Z, Buonamici S et al (2017) Basal-A triple-negative breast cancer cells selectively rely on RNA splicing for survival. Mol Cancer Ther 16(12):2849\u20132861","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"5515_CR47","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1101\/gad.241968.114","volume":"28","author":"Y Xu","year":"2014","unstructured":"Xu Y, Gao XD, Lee JH, Huang H, Tan H, Ahn J et al (2014) Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev 28(11):1191\u20131203","journal-title":"Genes Dev"},{"key":"5515_CR48","doi-asserted-by":"crossref","unstructured":"Harvey SE, Xu Y, Lin X, Gao XD, Qiu Y, Ahn J et al (2018) Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT.; http:\/\/www.rnajournal.org\/cgi\/doi\/10.1261\/rna","DOI":"10.1101\/301267"},{"key":"5515_CR49","doi-asserted-by":"crossref","unstructured":"Fu X, Tian M, Gu J, Cheng T, Ma D, Feng L et al (2017) SF3B1 mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients [Internet]. Vol. 8, Oncotarget. www.impactjournals.com\/oncotarget\/","DOI":"10.18632\/oncotarget.22983"},{"issue":"3\u20134","key":"5515_CR50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1101\/gad.319889.118","volume":"33","author":"H Zhang","year":"2019","unstructured":"Zhang H, Brown RL, Wei Y, Zhao P, Liu S, Liu X et al (2019) CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev 33(3\u20134):166\u2013179","journal-title":"Genes Dev"},{"issue":"47","key":"5515_CR51","doi-asserted-by":"publisher","first-page":"19280","DOI":"10.1073\/pnas.1214394109","volume":"109","author":"F Di Modugno","year":"2012","unstructured":"Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L et al (2012) Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci U S A 109(47):19280\u201319285","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"5515_CR52","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1038\/onc.2011.493","volume":"31","author":"K Horiguchi","year":"2012","unstructured":"Horiguchi K, Sakamoto K, Koinuma D, Semba K, Inoue A, Inoue S et al (2012) TGF-\u0392 drives epithelial-mesenchymal transition through EF1-mediated downregulation of ESRP. Oncogene 31(26):3190\u20133201","journal-title":"Oncogene"},{"issue":"S1","key":"5515_CR53","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.3233\/THC-THC228028","volume":"30","author":"D Cao","year":"2022","unstructured":"Cao D, Xue J, Huang G, An J, An W (2022) The role of splicing factor PRPF8 in breast cancer. Technol Health Care 30(S1):S293\u2013301","journal-title":"Technol Health Care"},{"key":"5515_CR54","doi-asserted-by":"crossref","unstructured":"Onyango DO, Lee G, Stark JM (2017) PRPF8 is important for BRCA1-mediated homologous recombination [Internet]. Vol. 8. www.impactjournals.com\/oncotarget","DOI":"10.18632\/oncotarget.21555"},{"key":"5515_CR55","doi-asserted-by":"crossref","unstructured":"Ibrahim LA, Wamsley B, Alghamdi N, Yusuf N, Sevier E, Hairston A et al (2023) Nova proteins direct synaptic integration of somatostatin interneurons through activity-dependent alternative splicing. Elife.;12","DOI":"10.7554\/eLife.86842"},{"issue":"19","key":"5515_CR56","doi-asserted-by":"publisher","first-page":"12792","DOI":"10.1074\/jbc.M807386200","volume":"284","author":"E Park","year":"2009","unstructured":"Park E, Lee MS, Baik SM, Cho EB, Son GH, Seong JY et al (2009) Nova-1 mediates glucocorticoid-induced inhibition of Pre-mRNA splicing of gonadotropin-releasing hormone transcripts. J Biol Chem 284(19):12792\u201312800","journal-title":"J Biol Chem"},{"key":"5515_CR57","doi-asserted-by":"crossref","unstructured":"Meldolesi J (2020) Alternative splicing by NOVA factors: from gene expression to cell physiology and pathology. International Journal of Molecular Sciences, vol 21. MDPI AG","DOI":"10.3390\/ijms21113941"},{"key":"5515_CR58","doi-asserted-by":"crossref","unstructured":"Tajima Y, Ito K, Yuan Y, Frank MO, Saito Y, Darnell RB (2023) NOVA1 acts on impact to regulate hypothalamic function and translation in inhibitory neurons. Cell Rep.;42(2)","DOI":"10.1016\/j.celrep.2023.112050"},{"issue":"18","key":"5515_CR59","doi-asserted-by":"publisher","first-page":"11818","DOI":"10.1093\/nar\/gku861","volume":"42","author":"O Villate","year":"2014","unstructured":"Villate O, Turatsinze JV, Mascali LG, Grieco FA, Nogueira TC, Cunha DA et al (2014) Nova1 is a master regulator of alternative splicing in pancreatic beta cells. Nucleic Acids Res 42(18):11818\u201311830","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"5515_CR60","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bbagrm.2016.08.006","volume":"1859","author":"JC Lin","year":"2016","unstructured":"Lin JC, Chi YL, Peng HY, Lu YH (2016) RBM4\u2013Nova1\u2013SRSF6 splicing cascade modulates the development of brown adipocytes. Biochim Biophys Acta Gene Regul Mech 1859(11):1368\u20131379","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"13","key":"5515_CR61","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.1093\/nar\/gkad469","volume":"51","author":"Z Yang","year":"2023","unstructured":"Yang Z, Dong P, Cao J, Lin N, Ma S, Cao R et al (2023) NOVA1 prevents overactivation of the unfolded protein response and facilitates chromatin access during human white adipogenesis. Nucleic Acids Res 51(13):6981\u20136998","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5515_CR62","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1111\/jcmm.13527","volume":"22","author":"X Yu","year":"2018","unstructured":"Yu X, Zheng H, Chan MTV, Wu WKK (2018) NOVA1 acts as an oncogene in melanoma via regulating FOXO3a expression. J Cell Mol Med 22(5):2622\u20132630","journal-title":"J Cell Mol Med"},{"issue":"4","key":"5515_CR63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/kjm2.12337","volume":"37","author":"XM Liu","year":"2021","unstructured":"Liu XM, Li XF, Li JC (2021) MiR-146a functions as a potential tumor suppressor in retinoblastoma by negatively regulate neuro-oncological ventral antigen-1. Kaohsiung J Med Sci 37(4):286\u2013293","journal-title":"Kaohsiung J Med Sci"},{"key":"5515_CR64","doi-asserted-by":"crossref","unstructured":"Sun S, Wang R, Yi S, Li S, Wang L, Wang J (2021) Roles of the microRNA-338-3p\/NOVA1 axis in retinoblastoma. Mol Med Rep.;23(5)","DOI":"10.3892\/mmr.2021.12033"},{"issue":"1","key":"5515_CR65","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11010-020-03904-6","volume":"476","author":"Y Cao","year":"2021","unstructured":"Cao Y, Zhang F, Wang H, Bi C, Cui J, Liu F et al (2021) LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p\/Nova1 axis. Mol Cell Biochem 476(1):279\u2013292","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"5515_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-016-0288-6","volume":"23","author":"YA Zhang","year":"2016","unstructured":"Zhang YA, Liu HN, Zhu JM, Zhang DY, Shen XZ, Liu TT (2016) RNA binding protein Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABAA Receptor-\u03b32. J Biomed Sci 23(1):1\u20139","journal-title":"J Biomed Sci"},{"key":"5515_CR67","doi-asserted-by":"crossref","unstructured":"Zhang YA, Zhu JM, Yin J, Tang WQ, Guo YM, Shen XZ et al (2014) High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma. PLoS ONE.;9(3)","DOI":"10.1371\/journal.pone.0090955"},{"key":"5515_CR68","doi-asserted-by":"crossref","unstructured":"Zhang T, Chen S, Peng Y, Wang C, Cheng X, Zhao R et al (2021) NOVA1-Mediated SORBS2 isoform promotes Colorectal Cancer Migration by activating the Notch Pathway. Front Cell Dev Biol.;9","DOI":"10.3389\/fcell.2021.673873"},{"key":"5515_CR69","doi-asserted-by":"crossref","unstructured":"Hong Ygang, Xu G shu, Yu G, yu, Zhou J dian, Liu Q, zhi, Ni J et al (2019) sheng,. The RNA binding protein neuro-oncological ventral antigen 1 (NOVA1) regulates IL-6 mRNA stability to enhance JAK2-STAT3 signaling in CRC. Surg Oncol.;31:67\u201374","DOI":"10.1016\/j.suronc.2019.09.009"},{"issue":"4","key":"5515_CR70","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3892\/ijmm.2017.3089","volume":"40","author":"H Li","year":"2017","unstructured":"Li H, Lv B, Kong L, Xia J, Zhu M, Hu L et al (2017) Nova1 mediates resistance of rat pheochromocytoma cells to hypoxia-induced apoptosis via the Bax\/Bcl-2\/caspase-3 pathway. Int J Mol Med 40(4):1125\u20131133","journal-title":"Int J Mol Med"},{"key":"5515_CR71","doi-asserted-by":"crossref","unstructured":"Zhi F, Wang Q, Deng D, Shao N, Wang R, Xue L et al (2014) MiR-181b-5p downregulates NOVA1 to suppress proliferation, migration and invasion and promote apoptosis in astrocytoma. PLoS ONE.;9(10)","DOI":"10.1371\/journal.pone.0109124"},{"issue":"7","key":"5515_CR72","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.21037\/tcr-19-2806","volume":"9","author":"M Liu","year":"2020","unstructured":"Liu M, Deng S, Xiao T, Gao J (2020) NOVA1 expression is associated with clinicopathological characteristics and prognosis in patients with small cell lung cancer. Transl Cancer Res 9(7):4373\u20134382","journal-title":"Transl Cancer Res"},{"key":"5515_CR73","doi-asserted-by":"crossref","unstructured":"Bl\u00e1zquez-Encinas R, Garc\u00eda-Vioque V, Caro-Cuenca T, Moreno-Montilla MT, Mangili F, Alors-P\u00e9rez E et al (2023) Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery. J Transl Med.;21(1)","DOI":"10.1186\/s12967-023-04754-8"},{"issue":"20","key":"5515_CR74","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.febslet.2015.09.009","volume":"589","author":"B Shen","year":"2015","unstructured":"Shen B, Zhang Y, Yu S, Yuan Y, Zhong Y, Lu J et al (2015) MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1. FEBS Lett 589(20):3205\u20133211","journal-title":"FEBS Lett"},{"issue":"3","key":"5515_CR75","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s10120-016-0623-3","volume":"20","author":"EK Kim","year":"2017","unstructured":"Kim EK, Yoon SO, Jung WY, Lee H, Kang Y, Jang YJ et al (2017) Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation. Gastric Cancer 20(3):438\u2013447","journal-title":"Gastric Cancer"},{"issue":"6","key":"5515_CR76","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/15476286.2020.1734372","volume":"17","author":"S Tang","year":"2020","unstructured":"Tang S, Zhao Y, He X, Zhu J, Chen S, Wen J et al (2020) Identification of NOVA family proteins as novel \u03b2-catenin RNA-binding proteins that promote epithelial-mesenchymal transition. RNA Biol 17(6):881\u2013891","journal-title":"RNA Biol"},{"issue":"19","key":"5515_CR77","doi-asserted-by":"publisher","first-page":"6664","DOI":"10.1093\/nar\/gkq494","volume":"38","author":"GA Roybal","year":"2010","unstructured":"Roybal GA, Jurica MS (2010) Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res 38(19):6664\u20136672","journal-title":"Nucleic Acids Res"},{"key":"5515_CR78","doi-asserted-by":"crossref","unstructured":"Liu B, Liu Z, Chen S, Ki M, Erickson C, Reis-Filho JS et al (2021) Mutant SF3B1 promotes AKT- and NF-\u03baB-driven mammary tumorigenesis. J Clin Invest.;131(1)","DOI":"10.1172\/JCI138315"},{"issue":"4","key":"5515_CR79","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/path.4483","volume":"235","author":"SL Maguire","year":"2015","unstructured":"Maguire SL, Leonidou A, Wai P, Marchi\u00f2 C, Ng CKY, Sapino A et al (2015) SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol 235(4):571\u2013580","journal-title":"J Pathol"},{"issue":"5","key":"5515_CR80","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/0008-5472.CAN-21-1843","volume":"82","author":"KM Lappin","year":"2022","unstructured":"Lappin KM, Barros EM, Jhujh SS, Irwin GW, McMillan H, Liberante FG et al (2022) Cancer-Associated SF3B1 mutations Confer a BRCA-Like Cellular phenotype and synthetic lethality to PARP inhibitors. Cancer Res 82(5):819\u2013830","journal-title":"Cancer Res"},{"key":"5515_CR81","doi-asserted-by":"crossref","unstructured":"Samy A, Ozdemir MK, Alhajj R (2023) Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research. Sci Rep.;13(1)","DOI":"10.1038\/s41598-023-29777-5"},{"issue":"22","key":"5515_CR82","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","volume":"19","author":"FALM Eskens","year":"2013","unstructured":"Eskens FALM, Ramos FJ, Burger H, O\u2019Brien JP, Piera A, De Jonge MJA et al (2013) Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res 19(22):6296\u20136304","journal-title":"Clin Cancer Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05515-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T03:06:20Z","timestamp":1735268780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05515-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5515"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05515-6","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"18"}}